<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242359</url>
  </required_header>
  <id_info>
    <org_study_id>2085</org_study_id>
    <nct_id>NCT00242359</nct_id>
  </id_info>
  <brief_title>A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma</brief_title>
  <official_title>A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernstein Clinical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bernstein Clinical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Management of animal induced occupational asthma is mainly avoidance, but this is not
      feasible for many occupations. Treatment with avoidance and conventional treatment is also
      not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and
      may be effective at reducing symptoms and disease progression in the animal handlers
      population.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    could not find subject population
  </why_stopped>
  <start_date type="Actual">November 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Allergy Induced Asthma</condition>
  <arm_group>
    <arm_group_label>omalizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open-label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omalizumab</intervention_name>
    <arm_group_label>omalizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ages 18-65

          2. occupation that involves close contact with animals

          3. stable dose of ICS for 30 days

          4. Skin test positive to one or more animals

          5. evidence of asthma on spirometry

          6. demonstrate PEFR variability-

        Exclusion Criteria:

          1. on allergen immunotherapy

          2. on prohibited medications

          3. unstable asthma

          4. recent URI

          5. known hypersensitivity to omalizumab-
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 17, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2005</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bernstein Clinical Research Center</investigator_affiliation>
    <investigator_full_name>Jonathan A. Bernstein, MD</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

